Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03888612 · ClinicalTrials.gov registry record · Phase 1
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
A Phase 1 study, sponsored by Arvinas.
- Completed
- Registry status
- Phase 1
- Development phase
- 248
- Enrollment target
NCT03888612: Completed Phase 1 study, sponsored by Arvinas.
NCT03888612 is a Phase 1 study that has completed, run by Arvinas. The registered enrollment target is 248 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (313% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03888612, a Phase 1 study, has completed, sponsored by Arvinas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 248 participants
- Enrollment target
Study Summary
Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic therapies for their castrate resistant disease (one of which must be enzalutamide or abiraterone).
Primary Outcome
First Cycle Dose limiting toxicities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug
Interventions
- DRUG ARV-110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2025-01-27 |
| Phase | Phase 1 |
What the finished NCT03888612 record still lists
NCT03888612 is an interventional study that assigns participants to a tested intervention. The registered 248 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (313% higher).
The record links to 0 conditions, and to 1 intervention - of which ARV-110 is the first listed.
NCT03888612 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03888612 about?
NCT03888612 is a clinical study titled "Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer". Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic therapies for their castrate resistant disease (one of which must be enzalutamide or abiraterone).
What is the current status of trial NCT03888612?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 248 participants. The study started on 2019-03-01. Estimated completion is 2025-01-27.
What interventions are being tested in trial NCT03888612?
The interventions under investigation include: ARV-110 (DRUG).
Who is sponsoring clinical trial NCT03888612?
This trial is sponsored by Arvinas, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03888612's enrollment target sits among peer trials
248 185th of 2000 higher than 1,814 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577911 · 248 participants
How is Social Connection Represented in the Brain?
- NCT04777994 · 248 participants · Phase 1
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- NCT04792489 · 248 participants · Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
- NCT04830137 · 248 participants · Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI